Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avecho BiotechnologyASX:AVE -5.00% 3-1 Month Momentum % is 76.00% as of Aug. 20, 2026. The stock has 1 warning sign investors should review. Among 1,386 Biotechnology companies, Avecho Biotechnology ranks better than 96.9% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-20), Avecho Biotechnology's 3-1 Month Momentum % is 76.00%.
The industry rank for Avecho Biotechnology's 3-1 Month Momentum % or its related term are showing as below:
ASX:AVE's 3-1 Month Momentum % is ranked better than 96.9% of 1386
companies
in the Biotechnology industry
Industry Median: -6.185
vs ASX:AVE: 76.00
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Avecho Biotechnology 3-1 Month Momentum % Related Terms
ASX:AVE vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Avecho Biotechnology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology (ASX:AVE) has a 3-1 Month Momentum % of 76.00% as of Aug. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Avecho Biotechnology and its competitors. According to the industry distribution chart, Avecho Biotechnology ranks #43 out of 1386 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Avecho Biotechnology's 3-1 Month Momentum % too high?
Avecho Biotechnology's current 3-1 Month Momentum % is 76.00%. Based on the distribution chart, Avecho Biotechnology ranks #43 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Avecho Biotechnology's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #43 out of 1386 companies for 3-1 Month Momentum %. This places Avecho Biotechnology in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Avecho Biotechnology and its competitors. Avecho Biotechnology's current 3-1 Month Momentum % is 76.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current 3-1 Month Momentum % of 76.00%. The current 3-1 Month Momentum % is 76.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current 3-1 Month Momentum % is 76.00% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVE has been successfully added to your 
